Global Retinal Disorders Therapy- Market

Retinal Disorders Therapy- Comprehensive Study by Disease Generation (Macular Degeneration, Dry Macular Degeneration, Wet Macular Degeneration, Diabetic Retinopathy, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Dosage Forms (Gels, Capsules & Tablets, Eye Drops, Ointments) Players and Region - Global Market Outlook to 2027

Retinal Disorders Therapy- Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Retinal Disorders Therapy-?
Retinal disorders are conditions that affect the light-sensitive tissue in the rear of the eye. Diabetic retinopathy and retinal detachment are two diseases that can occur. A medical emergency known as retinal detachment occurs when the retina retracts from the blood veins delivering oxygen. Retinal illnesses are in a variety of ways, but the majority of them result in visual problems. Any area of the retina, a thin layer of tissue on the inside rear wall of the eye, might be affected by retinal disease.

The market study is broken down and major geographies with country level break-up.

The vendor players focus on the technological advancement of therapy. The Retinal Disorders Therapy market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing on the production technologies, efficiency enhancement, and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge investment in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Retinal Disorders Therapy- market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Takeda Pharmaceuticals (United States), Bayer AG (Germany), Genentech, Inc. (United States), Santen Pharmaceutical Co., Ltd. (Japan), Regeneron Pharmaceuticals Inc. (United States), Graybug Vision, Inc. (United States), Acucela Inc. (United States), Pfizer Inc. (United States), Allergan plc (Ireland), Hoffmann-La Roche Ltd. (Switzerland), Kubota Pharmaceutical Holdings Co., Ltd. (United States) and Novartis AG (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Retinal Disorders Therapy- market by Type, Application and Region.

On the basis of geography, the market of Retinal Disorders Therapy- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Generation , the sub-segment i.e. Macular Degeneration will boost the Retinal Disorders Therapy- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Retinal Disorders Therapy- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage Forms, the sub-segment i.e. Gels will boost the Retinal Disorders Therapy- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In December 2021- Gyroscope Therapeutics will be acquired by Novartis, bringing with it a one-time gene therapy that potentially revolutionize the treatment of geographic atrophy, a primary cause of blindness.
In February 2022- The FDA authorized Kato Pharmaceuticals' investigational new drug application to conduct human trials with Resolve ERTM for the treatment of Vitreosmacular Attachment (VMA). This proprietary formulation of therapeutic medicine is designed to separate the vitreous from the retina, reducing the risk of numerous retinal disorders progressing. Kato can now test the effectiveness of Resolve ERTM on VMA, which can cause retinal tears, retinal detachment, and macular holes.


Market Trend
  • The growing incidence of retinal disorders
  • Increasing the need for effective and affordable treatment

Market Drivers
  • The increasing geriatric population
  • An increasing number of people suffering from diabetic retinopathy in America

Opportunities
  • Increasing prevalence of retinal disorders in both, developing as well as developed regions

Restraints
  • Side Effects of the Retinal Disorder Therapy

Challenges
  • Adoption of Non-Drug Pain Management Therapies


Key Target Audience
Manufacturers, Distributors and Suppliers, Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Disease Generation
  • Macular Degeneration
  • Dry Macular Degeneration
  • Wet Macular Degeneration
  • Diabetic Retinopathy
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Dosage Forms
  • Gels
  • Capsules & Tablets
  • Eye Drops
  • Ointments

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing geriatric population
      • 3.2.2. An increasing number of people suffering from diabetic retinopathy in America
    • 3.3. Market Challenges
      • 3.3.1. Adoption of Non-Drug Pain Management Therapies
    • 3.4. Market Trends
      • 3.4.1. The growing incidence of retinal disorders
      • 3.4.2. Increasing the need for effective and affordable treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Retinal Disorders Therapy-, by Disease Generation , Distribution Channel, Dosage Forms and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Retinal Disorders Therapy- (Value)
      • 5.2.1. Global Retinal Disorders Therapy- by: Distribution Channel (Value)
        • 5.2.1.1. Hospital Pharmacy
        • 5.2.1.2. Online Pharmacy
        • 5.2.1.3. Retail Pharmacy
      • 5.2.2. Global Retinal Disorders Therapy- by: Dosage Forms (Value)
        • 5.2.2.1. Gels
        • 5.2.2.2. Capsules & Tablets
        • 5.2.2.3. Eye Drops
        • 5.2.2.4. Ointments
      • 5.2.3. Global Retinal Disorders Therapy- Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Retinal Disorders Therapy- (Price)
  • 6. Retinal Disorders Therapy-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genentech, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Santen Pharmaceutical Co., Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Regeneron Pharmaceuticals Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Graybug Vision, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Acucela Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Allergan plc (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Kubota Pharmaceutical Holdings Co., Ltd. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Novartis AG (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Retinal Disorders Therapy- Sale, by Disease Generation , Distribution Channel, Dosage Forms and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Retinal Disorders Therapy- (Value)
      • 7.2.1. Global Retinal Disorders Therapy- by: Distribution Channel (Value)
        • 7.2.1.1. Hospital Pharmacy
        • 7.2.1.2. Online Pharmacy
        • 7.2.1.3. Retail Pharmacy
      • 7.2.2. Global Retinal Disorders Therapy- by: Dosage Forms (Value)
        • 7.2.2.1. Gels
        • 7.2.2.2. Capsules & Tablets
        • 7.2.2.3. Eye Drops
        • 7.2.2.4. Ointments
      • 7.2.3. Global Retinal Disorders Therapy- Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Retinal Disorders Therapy- (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Retinal Disorders Therapy-: by Distribution Channel(USD Million)
  • Table 2. Retinal Disorders Therapy- Hospital Pharmacy , by Region USD Million (2016-2021)
  • Table 3. Retinal Disorders Therapy- Online Pharmacy , by Region USD Million (2016-2021)
  • Table 4. Retinal Disorders Therapy- Retail Pharmacy , by Region USD Million (2016-2021)
  • Table 5. Retinal Disorders Therapy-: by Dosage Forms(USD Million)
  • Table 6. Retinal Disorders Therapy- Gels , by Region USD Million (2016-2021)
  • Table 7. Retinal Disorders Therapy- Capsules & Tablets , by Region USD Million (2016-2021)
  • Table 8. Retinal Disorders Therapy- Eye Drops , by Region USD Million (2016-2021)
  • Table 9. Retinal Disorders Therapy- Ointments , by Region USD Million (2016-2021)
  • Table 10. South America Retinal Disorders Therapy-, by Country USD Million (2016-2021)
  • Table 11. South America Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 12. South America Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 13. South America Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 14. Brazil Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 15. Brazil Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 16. Brazil Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 17. Argentina Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 18. Argentina Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 19. Argentina Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 20. Rest of South America Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 21. Rest of South America Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 22. Rest of South America Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 23. Asia Pacific Retinal Disorders Therapy-, by Country USD Million (2016-2021)
  • Table 24. Asia Pacific Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 25. Asia Pacific Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 26. Asia Pacific Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 27. China Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 28. China Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 29. China Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 30. Japan Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 31. Japan Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 32. Japan Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 33. India Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 34. India Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 35. India Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 36. South Korea Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 37. South Korea Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 38. South Korea Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 39. Taiwan Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 40. Taiwan Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 41. Taiwan Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 42. Australia Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 43. Australia Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 44. Australia Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 48. Europe Retinal Disorders Therapy-, by Country USD Million (2016-2021)
  • Table 49. Europe Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 50. Europe Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 51. Europe Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 52. Germany Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 53. Germany Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 54. Germany Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 55. France Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 56. France Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 57. France Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 58. Italy Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 59. Italy Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 60. Italy Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 61. United Kingdom Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 62. United Kingdom Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 63. United Kingdom Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 64. Netherlands Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 65. Netherlands Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 66. Netherlands Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 67. Rest of Europe Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 68. Rest of Europe Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 69. Rest of Europe Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 70. MEA Retinal Disorders Therapy-, by Country USD Million (2016-2021)
  • Table 71. MEA Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 72. MEA Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 73. MEA Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 74. Middle East Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 75. Middle East Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 76. Middle East Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 77. Africa Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 78. Africa Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 79. Africa Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 80. North America Retinal Disorders Therapy-, by Country USD Million (2016-2021)
  • Table 81. North America Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 82. North America Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 83. North America Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 84. United States Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 85. United States Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 86. United States Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 87. Canada Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 88. Canada Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 89. Canada Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 90. Mexico Retinal Disorders Therapy-, by Disease Generation USD Million (2016-2021)
  • Table 91. Mexico Retinal Disorders Therapy-, by Distribution Channel USD Million (2016-2021)
  • Table 92. Mexico Retinal Disorders Therapy-, by Dosage Forms USD Million (2016-2021)
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Retinal Disorders Therapy-: by Distribution Channel(USD Million)
  • Table 106. Retinal Disorders Therapy- Hospital Pharmacy , by Region USD Million (2022-2027)
  • Table 107. Retinal Disorders Therapy- Online Pharmacy , by Region USD Million (2022-2027)
  • Table 108. Retinal Disorders Therapy- Retail Pharmacy , by Region USD Million (2022-2027)
  • Table 109. Retinal Disorders Therapy-: by Dosage Forms(USD Million)
  • Table 110. Retinal Disorders Therapy- Gels , by Region USD Million (2022-2027)
  • Table 111. Retinal Disorders Therapy- Capsules & Tablets , by Region USD Million (2022-2027)
  • Table 112. Retinal Disorders Therapy- Eye Drops , by Region USD Million (2022-2027)
  • Table 113. Retinal Disorders Therapy- Ointments , by Region USD Million (2022-2027)
  • Table 114. South America Retinal Disorders Therapy-, by Country USD Million (2022-2027)
  • Table 115. South America Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 116. South America Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 117. South America Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 118. Brazil Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 119. Brazil Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 120. Brazil Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 121. Argentina Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 122. Argentina Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 123. Argentina Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 124. Rest of South America Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 125. Rest of South America Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 126. Rest of South America Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 127. Asia Pacific Retinal Disorders Therapy-, by Country USD Million (2022-2027)
  • Table 128. Asia Pacific Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 129. Asia Pacific Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 130. Asia Pacific Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 131. China Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 132. China Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 133. China Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 134. Japan Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 135. Japan Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 136. Japan Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 137. India Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 138. India Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 139. India Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 140. South Korea Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 141. South Korea Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 142. South Korea Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 143. Taiwan Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 144. Taiwan Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 145. Taiwan Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 146. Australia Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 147. Australia Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 148. Australia Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 149. Rest of Asia-Pacific Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 150. Rest of Asia-Pacific Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 151. Rest of Asia-Pacific Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 152. Europe Retinal Disorders Therapy-, by Country USD Million (2022-2027)
  • Table 153. Europe Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 154. Europe Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 155. Europe Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 156. Germany Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 157. Germany Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 158. Germany Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 159. France Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 160. France Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 161. France Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 162. Italy Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 163. Italy Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 164. Italy Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 165. United Kingdom Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 166. United Kingdom Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 167. United Kingdom Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 168. Netherlands Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 169. Netherlands Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 170. Netherlands Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 171. Rest of Europe Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 172. Rest of Europe Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 173. Rest of Europe Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 174. MEA Retinal Disorders Therapy-, by Country USD Million (2022-2027)
  • Table 175. MEA Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 176. MEA Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 177. MEA Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 178. Middle East Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 179. Middle East Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 180. Middle East Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 181. Africa Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 182. Africa Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 183. Africa Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 184. North America Retinal Disorders Therapy-, by Country USD Million (2022-2027)
  • Table 185. North America Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 186. North America Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 187. North America Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 188. United States Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 189. United States Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 190. United States Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 191. Canada Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 192. Canada Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 193. Canada Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 194. Mexico Retinal Disorders Therapy-, by Disease Generation USD Million (2022-2027)
  • Table 195. Mexico Retinal Disorders Therapy-, by Distribution Channel USD Million (2022-2027)
  • Table 196. Mexico Retinal Disorders Therapy-, by Dosage Forms USD Million (2022-2027)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Retinal Disorders Therapy-: by Distribution Channel USD Million (2016-2021)
  • Figure 5. Global Retinal Disorders Therapy-: by Dosage Forms USD Million (2016-2021)
  • Figure 6. South America Retinal Disorders Therapy- Share (%), by Country
  • Figure 7. Asia Pacific Retinal Disorders Therapy- Share (%), by Country
  • Figure 8. Europe Retinal Disorders Therapy- Share (%), by Country
  • Figure 9. MEA Retinal Disorders Therapy- Share (%), by Country
  • Figure 10. North America Retinal Disorders Therapy- Share (%), by Country
  • Figure 11. Global Retinal Disorders Therapy- share by Players 2021 (%)
  • Figure 12. Global Retinal Disorders Therapy- share by Players (Top 3) 2021(%)
  • Figure 13. Global Retinal Disorders Therapy- share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Takeda Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 16. Takeda Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 17. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 19. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Genentech, Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Santen Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Santen Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2021
  • Figure 23. Regeneron Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Regeneron Pharmaceuticals Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Graybug Vision, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Graybug Vision, Inc. (United States) Revenue: by Geography 2021
  • Figure 27. Acucela Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Acucela Inc. (United States) Revenue: by Geography 2021
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 32. Allergan plc (Ireland) Revenue: by Geography 2021
  • Figure 33. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2021
  • Figure 35. Kubota Pharmaceutical Holdings Co., Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Kubota Pharmaceutical Holdings Co., Ltd. (United States) Revenue: by Geography 2021
  • Figure 37. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 39. Global Retinal Disorders Therapy-: by Distribution Channel USD Million (2022-2027)
  • Figure 40. Global Retinal Disorders Therapy-: by Dosage Forms USD Million (2022-2027)
  • Figure 41. South America Retinal Disorders Therapy- Share (%), by Country
  • Figure 42. Asia Pacific Retinal Disorders Therapy- Share (%), by Country
  • Figure 43. Europe Retinal Disorders Therapy- Share (%), by Country
  • Figure 44. MEA Retinal Disorders Therapy- Share (%), by Country
  • Figure 45. North America Retinal Disorders Therapy- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Takeda Pharmaceuticals (United States)
  • Bayer AG (Germany)
  • Genentech, Inc. (United States)
  • Santen Pharmaceutical Co., Ltd. (Japan)
  • Regeneron Pharmaceuticals Inc. (United States)
  • Graybug Vision, Inc. (United States)
  • Acucela Inc. (United States)
  • Pfizer Inc. (United States)
  • Allergan plc (Ireland)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Kubota Pharmaceutical Holdings Co., Ltd. (United States)
  • Novartis AG (Switzerland)
Select User Access Type

Key Highlights of Report


Apr 2022 249 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Retinal Disorders Therapy- Market Quantitative research analysis
Global Retinal Disorders Therapy- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Takeda Pharmaceuticals (United States), Bayer AG (Germany), Genentech, Inc. (United States), Santen Pharmaceutical Co., Ltd. (Japan), Regeneron Pharmaceuticals Inc. (United States), Graybug Vision, Inc. (United States), Acucela Inc. (United States), Pfizer Inc. (United States), Allergan plc (Ireland), Hoffmann-La Roche Ltd. (Switzerland), Kubota Pharmaceutical Holdings Co., Ltd. (United States) and Novartis AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Retinal Disorders Therapy- Market to reach USD Million by 2027.

Know More About Global Retinal Disorders Therapy- Market Report?

Have a Query? Click Here

Other Related Reports

Laser Cancer Therapy Comprehensive Study by Application (Dermatology and Aesthetics, Dental, Ophthalmology, Cardiovascular, Others), End-users (Hospitals, Specialty Clinics, Cancer and Radiation Ther...
$ 3800
Smart Vision Aids Comprehensive Study by Type (Audio-visual Conversion, Implantable BMI, Non-implantable BMI), Application (Central Vision Loss, Blurry Vision, Blind Spot, Others), Product Type (Smar...
$ 3800
Metaverse in Healthcare Comprehensive Study by Technology (Virtual Reality, Augmented Reality, Mixed Reality, Artificial Intelligence), Device (Virtual Reality Headsets, Augmented Reality Devices, Mi...
$ 3800
VR in Elderly Care Comprehensive Study by Type (Non-immersive Virtual Reality, Fully Immersive Virtual Reality, Semi-Immersive Virtual Reality, Augmented Reality, Collaborative VR), Application (Medi...
$ 3800
Wellness App Comprehensive Study by Type (Exercise and Weight Loss, Diet and Nutrition, Activity Tracking, Others), Device (Smartphones, Tablets, Wearable Devices), Operating system (IOS, Android) Pl...
$ 3800
Healthcare Additive Manufacturing Comprehensive Study by Application (Medical Implants, Prosthetics, Wearable Devices, Tissue Engineering, Others), Technology (Stereolithography, Deposition Modeling,...
$ 3800